2025
Correcting SUVR bias by accounting for radiotracer clearance in tissue: A validation study with [18F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts.
Oh M, Honhar P, Carson R, Hillmer A, Varrone A. Correcting SUVR bias by accounting for radiotracer clearance in tissue: A validation study with [18F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts. Cerebrovascular And Brain Metabolism Reviews 2025, 271678x251322407. PMID: 39981611, PMCID: PMC11846093, DOI: 10.1177/0271678x251322407.Peer-Reviewed Original ResearchLRRK2, lysosome damage, and Parkinson's disease
Bentley-DeSousa A, Clegg D, Ferguson S. LRRK2, lysosome damage, and Parkinson's disease. Current Opinion In Cell Biology 2025, 93: 102482. PMID: 39983584, DOI: 10.1016/j.ceb.2025.102482.Peer-Reviewed Original ResearchConceptsLRRK2 kinase activityKinase activitySubstrate of LRRK2Rab familySmall GTPasesLysosomal biologyDamaged lysosomesEndolysosomal membranesRegulatory mechanismsNormal biologyPathogenesis of Parkinson's diseaseLRRK2Repair mechanismsLysosomal damageLysosomesBiologyGTPaseParkinson's diseaseRabGABARAPActivityCCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models
Leser F, Júnyor F, Pagnoncelli I, Delgado A, Medeiros I, Nóbrega A, Andrade B, de Lima M, da Silva N, Jacob L, Boyé K, Geraldo L, de Souza A, Maron-Gutierrez T, Castro-Faria-Neto H, Follmer C, Braga C, Neves G, Eichmann A, Romão L, Lima F. CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models. Journal Of Neuroinflammation 2025, 22: 31. PMID: 39894839, PMCID: PMC11789347, DOI: 10.1186/s12974-024-03318-x.Peer-Reviewed Original ResearchConceptsMouse model of PDModel of PDMouse modelDopaminergic neuronsNeuron-microglia communicationNeuron-glia communicationParkinson's diseaseCCR7-dependent mannerMicroglial cell activationCCR7 expressionCCL21-CCR7Progressive degenerative diseaseCCR7 receptorMicroglial cell migrationInflammatory profileChemokine CCL21Cell activationCCL21Therapeutic strategiesChemokine inhibitorsTherapeutic implicationsMicroglial activationReceptor pathwayCCR7Behavioral deficitsEvidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Marek K, Russell D, Concha-Marambio L, Choi S, Jennings D, Brumm M, Coffey C, Brown E, Seibyl J, Stern M, Soto C, Siderowf A. Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study. EBioMedicine 2025, 112: 105567. PMID: 39893720, PMCID: PMC11835612, DOI: 10.1016/j.ebiom.2025.105567.Peer-Reviewed Original ResearchConceptsDementia with Lewy bodiesCross-sectional studyCognitive symptomsParkinson Associated Risk Syndrome StudyPrevention StudyYear follow-upOlder individualsDopamine transporter imagingHigh riskSyndrome studiesParticipantsParkinson's diseaseHyposmic individualsFollow-upSynuclein pathologySymptomsHyposmicsDepartment of DefenseU.S. Department of DefenseIndividualsRiskLewy bodiesClinical parkinsonismMichael J. Fox FoundationDementiaRadiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients
Droby A, Yoffe-Vasiliev A, Atias D, Fraser K, Mabrouk O, Omer N, Bar-Shira A, Gana-Weisz M, Goldstein O, Artzi M, Ben Bashat D, Alcalay R, Orr-Urtreger A, Shirvan J, Cedarbaum J, Giladi N, Mirelman A, Thaler A. Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients. Npj Parkinson's Disease 2025, 11: 7. PMID: 39753572, PMCID: PMC11698941, DOI: 10.1038/s41531-024-00854-4.Peer-Reviewed Original ResearchStriatal binding ratiosLRRK2-PD patientsFunctional connectivityLeft fronto-occipital fasciculusCerebrospinal fluidGray matter volumeDeep gray matter volumesRegional brain volumesWhole-brain gray matterNeuromelanin MRIFronto-occipital fasciculusLRRK2-PDWhite matterParkinson's diseaseLeft caudateMatter volumeReduced FCParkinson's disease patientsWhole-brainBrain volumeRadiological markersHealthy controlsFractional anisotropyRadiological measurementsPatients
2024
Transcranial optogenetic brain modulator for precise bimodal neuromodulation in multiple brain regions
Shin H, Nam M, Lee S, Yang S, Yang E, Jung J, Kim H, Woo J, Cho Y, Yoon Y, Cho I. Transcranial optogenetic brain modulator for precise bimodal neuromodulation in multiple brain regions. Nature Communications 2024, 15: 10423. PMID: 39613730, PMCID: PMC11607408, DOI: 10.1038/s41467-024-54759-0.Peer-Reviewed Original ResearchConceptsBrain regionsBrain modulesModulation of brain functionTranscranial brain stimulationMultiple brain regionsUpconversion particlesSymptoms of Parkinson's diseaseOptical crosstalkStudy of neural circuitsFood competition testBrain dysfunctionExternal light sourceLight sourcesBrain functionStudy of complex behaviorsSpatial resolutionNeural circuitsBrain disordersDevelopment of treatmentsOptogenetic techniquesBrain stimulationNeural populationsBrainParkinson's diseaseNeuromodulationQuantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples
Liu Y, Yang M, Fraser K, Graham D, Weinreb P, Weihofen A, Hirst W, Cedarbaum J, Pepinsky B. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. Journal Of Pharmacology And Experimental Therapeutics 2024, 392: 100003. PMID: 39892989, DOI: 10.1124/jpet.124.002199.Peer-Reviewed Original ResearchCentral nervous systemCerebrospinal fluidMeso Scale DiscoveryCentral nervous system compartmentDrug concentrationsA-synCerebrospinal fluid samplesParkinson's diseasePassive immunotherapy approachesSite of actionImmunotherapy approachesLow drug concentrationsImmunotherapy trialsHealthy volunteersSystemic compartmentDrug-target interactionsCSF samplesObserved doseNervous systemTherapeutic targetA-syn levelsClinical samplesTime-dependent bindingComplex formationCross-linking methodPresynaptic terminal integrity is associated with glucose metabolism in Parkinson’s disease
Wang W, Wang Y, Xu L, Liu X, Hu Y, Li J, Huang Q, Ren S, Huang Y, Guan Y, Li Y, Hua F, Ye Q, Xie F. Presynaptic terminal integrity is associated with glucose metabolism in Parkinson’s disease. European Journal Of Nuclear Medicine And Molecular Imaging 2024, 52: 1510-1519. PMID: 39572432, DOI: 10.1007/s00259-024-06993-3.Peer-Reviewed Original ResearchPositron emission tomographyDopamine transporterSynaptic densityGlucose metabolismDopamine transporter availabilityPD patientsPost-commissural caudateParkinson's diseaseReduced synaptic densityAssociated with glucose metabolismDopaminergic transporterMethodsA totalHealthy controlsSynaptic vesicle protein 2PatientsEmission tomographyCaudatePD groupMetabolic patternsTerminal integrityProtein 2DiseaseNC groupCaudate regionsMetabolismNeuroimaging Biomarkers in Parkinson’s Disease
Holmes S, Tinaz S. Neuroimaging Biomarkers in Parkinson’s Disease. Advances In Neurobiology 2024, 40: 617-663. PMID: 39562459, DOI: 10.1007/978-3-031-69491-2_21.Peer-Reviewed Original ResearchConceptsPublic health burdenNeuroimaging biomarkersTreatment developmentRisk of developing PDParkinson's diseaseHealth burdenDiagnosis of PDMultimodal neuroimaging techniquesIdiopathic Parkinson's diseaseNon-motorDifferential diagnosis of PDNeuroimaging techniquesProdromal phaseDifferential diagnosisSymptomatic treatmentDisease progressionClinical applicationBiomarkersSingle-cell transcriptomic and proteomic analysis of Parkinson’s disease brains
Zhu B, Park J, Coffey S, Russo A, Hsu I, Wang J, Su C, Chang R, Lam T, Gopal P, Ginsberg S, Zhao H, Hafler D, Chandra S, Zhang L. Single-cell transcriptomic and proteomic analysis of Parkinson’s disease brains. Science Translational Medicine 2024, 16: eabo1997. PMID: 39475571, DOI: 10.1126/scitranslmed.abo1997.Peer-Reviewed Original ResearchConceptsProteomic analysisAlzheimer's diseasePrefrontal cortexBrain cell typesGenetics of PDParkinson's diseaseCell-cell interactionsChaperone expressionSingle-nucleus transcriptomesExpressed genesTranscriptional changesPostmortem human brainPostmortem brain tissueDiseased brainSynaptic proteinsSingle-cellDown-regulationBrain cell populationsBrain regionsCell typesNeurodegenerative disordersLate-stage PDParkinson's disease brainsDisease etiologyNeuronal vulnerabilityGlottal Insufficiency and Parkinson’s Disease: A Scoping Review of Vocal Fold Medialization Procedures
Garabedian M, Keltz A, Lerner M, Brackett A, Leydon C. Glottal Insufficiency and Parkinson’s Disease: A Scoping Review of Vocal Fold Medialization Procedures. Journal Of Voice 2024 PMID: 39438169, DOI: 10.1016/j.jvoice.2024.09.034.Peer-Reviewed Original Research In PressImprove vocal functionJoanna Briggs Institute checklistDiagnosis of participantsGrey literature resourcesProspective research designEnrollment of participantsQuality of lifeDebilitating symptom of Parkinson's diseaseScoping reviewInstitute checklistEnglish-language publicationsGeneralizability of findingsParticipant demographicsQuality of research articlesOutcome measuresAuditory-perceptualParkinson's diseaseEligibility criteriaInclusionary criteriaBiomedical databasesControl participantsSpeech therapyDebilitating symptomsPwPDVocal functionValidating new symptom emergence as a patient-centric outcome measure for PD clinical trials
Zou H, Stebbins G, Simuni T, Luo S, Cedarbaum J. Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials. Parkinsonism & Related Disorders 2024, 128: 107118. PMID: 39353265, DOI: 10.1016/j.parkreldis.2024.107118.Peer-Reviewed Original ResearchPD clinical trialsClinical trialsEmergent symptomsPhase 3 clinical trialsPhase 3 studySlowing of disease progressionOutcome measuresParkinson's diseaseDe novo Parkinson's diseaseMDS-UPDRSItem-level dataFrequency of ESSymptomatic medicationsFrequent administrationMonths of observationEfficacy assessmentDisease progressionSymptom emergenceRating ScaleItem responsesIb and IIUrate elevationTrialsSocioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease
Cayir S, Tezel M, Matuskey D. Socioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease. Journal Of Geriatric Psychiatry And Neurology 2024, 38: 143-149. PMID: 39244698, DOI: 10.1177/08919887241281062.Peer-Reviewed Original ResearchMedian household incomeDopaminergic functionHealthy individualsSocioenvironmental factorsEducation levelHousehold incomeZIP Code Tabulation AreasBrain dopaminergic functionDopamine transporter availabilityResidential zip codeParkinson's Progression Markers InitiativeParkinson's diseaseNo significant associationAmerican Community SurveyDAT availabilityDopamine transporterZip codesClinical dataHealthy subjectsSocioenvironmental variablesCommunity SurveySignificant associationPD groupPoverty ratesStudy findingsClinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkersPhosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits
Kokotos A, Antoniazzi A, Unda S, Ko M, Park D, Eliezer D, Kaplitt M, De Camilli P, Ryan T. Phosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits. Science Advances 2024, 10: eadn6016. PMID: 39167658, PMCID: PMC11338267, DOI: 10.1126/sciadv.adn6016.Peer-Reviewed Original ResearchConceptsPhosphoglycerate kinase 1Metabolic deficitsExpressions of Phosphoglycerate Kinase 1Dopamine axonsParkinson's diseasePD-associated pathologyViral expressionLoss of functionNeuronal glycolysisSusceptibility lociIn vivoFamilial Parkinson's diseasePD therapeuticsMetabolic lesionsProduction kineticsKinase 1Mitochondrial integrityPhosphoglycerate kinaseBioenergetic deficitsSynaptic dysfunctionGenetic originDeficitsPARK7/DJ-1PhosphoglycerateModifications on histone tails in Parkinson's disease.
Mao Q, Luo Z, Wang K, Chen B, Wang Z, Zhang Y, Wang X, Luo X. Modifications on histone tails in Parkinson's disease. SciBase Neurology 2024, 2 PMID: 39145143, PMCID: PMC11323098, DOI: 10.52768/neurology/1017.Peer-Reviewed Original ResearchHistone modificationsEpigenetic regulation of genesGene regulatory regionsGene expression regulationHistone tail modificationsRegulation of genesHistone marksChromatin structureRepressive marksRegulatory regionsExpression regulationHistone tailsTail modificationsHistone H2AEpigenetic modificationsEpigenetic regulationEpigenetic mechanismsHistoneGene expressionGenesGSK-J4Neural stem cellsA-synucleinEnvironmental factorsParkinson's diseaseVerbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis
Kennedy E, Liebel S, Lindsey H, Vadlamani S, Lei P, Adamson M, Alda M, Alonso-Lana S, Anderson T, Arango C, Asarnow R, Avram M, Ayesa-Arriola R, Babikian T, Banaj N, Bird L, Borgwardt S, Brodtmann A, Brosch K, Caeyenberghs K, Calhoun V, Chiaravalloti N, Cifu D, Crespo-Facorro B, Dalrymple-Alford J, Dams-O’Connor K, Dannlowski U, Darby D, Davenport N, DeLuca J, Diaz-Caneja C, Disner S, Dobryakova E, Ehrlich S, Esopenko C, Ferrarelli F, Frank L, Franz C, Fuentes-Claramonte P, Genova H, Giza C, Goltermann J, Grotegerd D, Gruber M, Gutierrez-Zotes A, Ha M, Haavik J, Hinkin C, Hoskinson K, Hubl D, Irimia A, Jansen A, Kaess M, Kang X, Kenney K, Keřková B, Khlif M, Kim M, Kindler J, Kircher T, Knížková K, Kolskår K, Krch D, Kremen W, Kuhn T, Kumari V, Kwon J, Langella R, Laskowitz S, Lee J, Lengenfelder J, Liou-Johnson V, Lippa S, Løvstad M, Lundervold A, Marotta C, Marquardt C, Mattos P, Mayeli A, McDonald C, Meinert S, Melzer T, Merchán-Naranjo J, Michel C, Morey R, Mwangi B, Myall D, Nenadić I, Newsome M, Nunes A, O’Brien T, Oertel V, Ollinger J, Olsen A, de la Foz V, Ozmen M, Pardoe H, Parent M, Piras F, Piras F, Pomarol-Clotet E, Repple J, Richard G, Rodriguez J, Rodriguez M, Rootes-Murdy K, Rowland J, Ryan N, Salvador R, Sanders A, Schmidt A, Soares J, Spalleta G, Španiel F, Sponheim S, Stasenko A, Stein F, Straube B, Thames A, Thomas-Odenthal F, Thomopoulos S, Tone E, Torres I, Troyanskaya M, Turner J, Ulrichsen K, Umpierrez G, Vecchio D, Vilella E, Vivash L, Walker W, Werden E, Westlye L, Wild K, Wroblewski A, Wu M, Wylie G, Yatham L, Zunta-Soares G, Thompson P, Pugh M, Tate D, Hillary F, Wilde E, Dennis E. Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis. Brain Sciences 2024, 14: 669. PMID: 39061410, PMCID: PMC11274572, DOI: 10.3390/brainsci14070669.Peer-Reviewed Original ResearchAttention-deficit/hyperactivity disorderVerbal learningNeuropsychiatric conditionsTraumatic brain injuryYears of educationMild cognitive impairmentComorbid disordersAttention-deficit/hyperactivityBipolar disorderMemory deficitsMemory performanceMemory recallClinical groupsMega-analysisCognitive impairmentEffects of dementiaAssociated with dementiaMemoryBrain injurySchizophreniaMemory impactDisordersDepressionParkinson's diseaseUnique participantsGray Matter Atrophy in a 6-OHDA-induced Model of Parkinson’s Disease
Kumari S, Rana B, Kumaran S, Chaudhary S, Jain S, Srivastava A, Rajan R. Gray Matter Atrophy in a 6-OHDA-induced Model of Parkinson’s Disease. Neuroscience 2024, 551: 217-228. PMID: 38843989, DOI: 10.1016/j.neuroscience.2024.05.029.Peer-Reviewed Original ResearchVolume-based morphometryGray matter volumeMachine learningMagnetic resonance imagingClassification accuracyGray matter atrophySham controlsSupport vector machine (SVM)-based algorithmContralateral rotational behaviorUnilateral 6-hydroxydopamineIncrease classification accuracyAssociated with progressionMatter volumeModel of Parkinson's diseaseParkinson's diseaseBrain regionsBasal ganglia-thalamocortical circuitsPD modelSubcortical brain regionsGMV changesGray matter volume atrophyBrain morphometric changesInternal capsuleStudy of alterationsSubstantia nigraValidity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers
Schejter‐Margalit T, Binyamin N, Thaler A, Maidan I, Cedarbaum J, Orr‐Urtreger A, Weisz M, Goldstein O, Giladi N, Mirelman A, Kizony R. Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers. European Journal Of Neurology 2024, 31: e16327. PMID: 38743695, PMCID: PMC11235808, DOI: 10.1111/ene.16327.Peer-Reviewed Original ResearchKnown-groups validityWeekly Calendar Planning ActivityColor Trails TestActivities of Daily Living ScaleKnown-groups construct validityIdiopathic PDPhysical Activity ScaleDaily Living ScaleEngland Activities of Daily Living ScaleNonmanifesting carriersPD to healthy controlsIdiopathic PD groupMontreal Cognitive AssessmentEcological validitySE-ADLActivity ScaleCompare personsConstruct validityOutcome measuresConvergent validityCognitive AssessmentGBA carriersEngland ActivitiesParkinson's diseaseCognitive testsMild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease
Thaler A, Livne V, Rubinstein E, Omer N, Faust-Socher A, Cohen B, Giladi N, Shirvan J, Cedarbaum J, Gana-Weisz M, Goldstein O, Orr-Urtreger A, Alcalay R, Mirelman A. Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease. Parkinsonism & Related Disorders 2024, 123: 106970. PMID: 38691978, DOI: 10.1016/j.parkreldis.2024.106970.Peer-Reviewed Original ResearchMild cognitive impairmentIdiopathic PDMovement Disorder SocietyIncidence of mild cognitive impairmentFrequency of mild cognitive impairmentDiagnosis of mild cognitive impairmentCognitive impairmentLRRK2-PDLevel I criteriaParkinson's diseaseLevel II criteriaCarriers of mutationsMotor symptom onsetHoehn and YahrGBA1-PDCognitive batteryGender-matched controlsCognitive domainsEarly-stage PDI criteriaClinical characteristicsPD cohortDisorder SocietySymptom onsetHealthy adults
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply